Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Published on by Cell Biologist

Prof. Francesca Santilli | Signal Transduction Mechanisms | Research Excellence Award

Department of Medicine and Aging Science, University of Chieti-Pescara “G. d’Annunzio”Chieti | Italy

Francesca Santilli, MD, PhD, is a leading physician-scientist whose work has substantially advanced the understanding of platelet biology, thrombo-inflammation, and cardio-metabolic disease. Her research focuses on mechanisms of platelet activation, interindividual variability in response to low-dose aspirin, and the interplay between inflammation, oxidative stress, and metabolic dysfunction. She has led major national and international projects, including studies on oxidative stress regulation in aspirin-treated diabetes, peripheral blood megakaryocyte maturation, and the effects of JAK inhibitors on thrombopoiesis in inflammatory disease. Her work has also contributed key insights into biomarkers—such as proteomic signatures, microRNAs, and extracellular vesicles—for cardiovascular and metabolic risk stratification. Additional research explores megakaryocyte biology, accelerated platelet turnover, and the impact of emerging therapies including GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors. Through extensive collaborations across molecular medicine, proteomics, rheumatology, cardiology, and infectious diseases, she has established interdisciplinary frameworks linking platelet function to diabetes, obesity, MASLD, and vascular disease. With over 160 high-impact publications and leadership roles in several scientific networks, her research continues to inform clinical translation and therapeutic optimization in thrombosis, hemostasis, and metabolic disorders.

Profiles: Google Scholar | Scopus

Featured Publications: 

antilli, F., Vazzana, N., Liani, R., Guagnano, M. T., & Davì, G. (2012). Platelet activation in obesity and metabolic syndrome. Obesity Reviews, 13(1), 27–42.

Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., & Patrono, C. (2009). Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin “resistance.” Journal of the American College of Cardiology, 53(8), 667–677.

Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., … & Patrono, C. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10(7), 1220–1230.

Caricato, A., Conti, G., Della Corte, F., Mancino, A., Santilli, F., Sandroni, C., … & Antonelli, M. (2005). Effects of PEEP on the intracranial system of patients with head injury and subarachnoid hemorrhage: The role of respiratory system compliance. Journal of Trauma and Acute Care Surgery, 58(3), 571–576.

Santilli, F., Vazzana, N., Bucciarelli, L. G., & Davì, G. (2009). Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Current Medicinal Chemistry, 16(8), 940–952.

Di Castelnuovo, A., Bonaccio, M., Costanzo, S., Gialluisi, A., Antinori, A., … Santilli, F., … & Iacoviello, L. (2020). Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: Survival analysis and machine learning-based findings from the multicentre Italian study. Nutrition, Metabolism and Cardiovascular Diseases, 30(11), 1899–1913.

Vazzana, N., Santilli, F., Cuccurullo, C., & Davì, G. (2009). Soluble RAGE in internal medicine. Internal and Emergency Medicine, 4(5), 389–401.

Davì, G., Santilli, F., & Patrono, C. (2010). Nutraceuticals in diabetes and metabolic syndrome. Cardiovascular Therapeutics, 28(4), 216–226.

Chiarelli, F., Santilli, F., & Mohn, A. (2000). Role of growth factors in the development of diabetic complications. Hormone Research in Paediatrics, 53(2), 53–67.

Davì, G., Chiarelli, F., Santilli, F., Pomilio, M., Vigneri, S., Falco, A., … & Basili, S. (2003). Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation, 107(25), 3199–3203.

Manigrasso, M. R., Ferroni, P., Santilli, F., Taraborelli, T., Guagnano, M. T., … & Davì, G. (2005). Association between circulating adiponectin and interleukin-10 levels in android obesity: Effects of weight loss. The Journal of Clinical Endocrinology & Metabolism, 90(10), 5876–5879.

Sabir khan | Epidemiology | Best Researcher Award

Published on by Cell Biologist

Dr. Sabir khan | Epidemiology | Best Researcher Award

Jinfeng Laboratory, Chongqing | China

Dr. Sabir Khan’s research focuses on transcription factors, gene expression regulation, and the biosynthetic pathways of antibiotics. His work integrates microbiology and synthetic biology to explore the molecular mechanisms underlying fungal and bacterial diseases. He has contributed significantly to understanding antifungal susceptibility and the development of resistance mechanisms in pathogenic microorganisms. In addition, his studies on glioma (brain cancer) investigate microbial interactions and secondary metabolites that may offer therapeutic potential. His research extends to fermentation technology, optimizing microbial processes for enhanced antibiotic production. Dr. Khan’s postdoctoral research emphasizes ecological and synthetic biology approaches to manipulate microbial pathways for improved biosynthetic yields. By combining molecular genetics, microbiological assays, and bioinformatics tools, his work aims to identify regulatory networks and transcriptional controls involved in secondary metabolite production. Through this multidisciplinary approach, Dr. Khan contributes to the advancement of microbial biotechnology and the development of novel antimicrobial and anticancer strategies.

Profiles: Google Scholar | Orcid

Featured Publications: 

Khan, S., Bilal, H., Khan, M. N., Fang, W., Chang, W., Yin, B., Song, N. J., et al. (2024). Interleukin inhibitors and associated risk of candidiasis. Frontiers in Immunology, 28 March 2024.

Khan, S., Bilal, H., Shafiq, M., Zhang, D., Awais, M., Chen, C., Khan, M. N., et al. (2024). Distribution of Aspergillus species and risk factors for Aspergillosis from mainland China: A systematic analysis. Therapeutic Advances in Infectious Disease, 17 April 2024. https://doi.org/10.1177/2049936124xxxxx
(IF: 5.7)

Khan, S., Xu, X., Song, J., Wu, P., Liu, X., Liu, J., Chen, K., Xu, Z., Wu, H., & Zhang, B. (2022). Crosstalk of TetR-like regulator SACE_4839 and a nitrogen regulator for erythromycin biosynthesis. Applied Microbiology and Biotechnology, 106, 12345–12356.

Liu, Y.#, Khan, S.#, Wu, P.#, Liu, L., Li, B., Ni, J., Zhang, H., Chen, K., Wu, H., & Zhang, B. (2021). Uncovering and engineering mini-regulatory network of the TetR-family regulator SACE_0303 for yield improvement of erythromycin in Saccharopolyspora erythraea. Frontiers in Bioengineering and Biotechnology, 9, 715234.

Khan, S.†, Cai, L.†, Bilal, H., Khan, M. N., Fang, W., Zhang, D., & Yao, F. (2023). An 11-year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China. Scientific Reports, 13, 5678.

Khan, S.†, Hou, B., Khan, M. N., Shafiq, M., Cai, L.†, Fang, W., Wang, Q., Bilal, H., & Zeng, Y. (2025). A three-year retrospective analysis of microbial species and key biomarkers associated with wound infections in Shantou Hospital, China. Frontiers in Cellular and Infection Microbiology, 15, 15456.

Khan, S., Hameed, M. F., Zafar, I., Bibi, R., Mohany, M., Nazir, S., Kamal, M. A., & Shafiq, M. (2024). Synthesis, characterization, and pharmacological evaluation of Zn4O(BDC)3: Anticancer, antidiabetic, and drug delivery potential. Medicinal Chemistry, 20(3), 145–157.

Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Bahauddin Zakariya Univeristy |Pakistan

Dr. Muhammad Junaid Anwar is a rising scholar in Food Science & Technology whose work spans bioactive compounds, dairy protein‐based nanoencapsulation, food safety, and nutraceutical applications. According to Google Scholar, he has authored over 20 peer-reviewed articles and accumulated more than 270 citations to date, reflecting an h-index of 8.  His research includes investigations into olive oil polyphenols for cancer prevention, development of casein-based nanoencapsulation for managing cow’s milk allergy, optimization of ultrasonication pre-treatments for microbial reduction in fresh produce, and exploration of isoflavones and resveratrol in anticancer contexts. Through a blend of experimental and review work, he advances both the applied and mechanistic understanding of functional foods and health-promoting ingredients.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Anwar, M. J., Anwar, M. H., Imran, M., Noman, A. M., Hussain, M., Raza, H., … & Selim, S. (2025). Olive oil polyphenols: A promising approach for cancer prevention and therapy. Food Science & Nutrition, 13(9), e70976.

Anwar, M. J., Hameed, A., Khan, M. U., Mazhar, A., & Manzoor, H. M. I. (2025). Development and exploration of casein-based nano-encapsulation of mangiferin for cow milk allergy management and immunomodulation. Food Bioscience, 66, 106278.

Javed, M. S., Nawaz, H., Filza, F., Anwar, M. J., Shah, F. U. H., Ali, U., … & Nayik, G. A. (2025). Optimization of calcium chloride and ultrasonication pre-treatment to mitigate the microbial load on fresh carrots using response surface methodology. Ultrasonics Sonochemistry, 116, 107311.

Ul Hassan, M. H., Shahbaz, M., Imran, M., Momal, U., Naeem, H., Mujtaba, A., Hussain, M., Anwar, M. J., Alsagaby, S. A., Al Abdulmonem, W., Yehuala, T. F., & Mostafa, E. M. (2025). Isoflavones: Promising natural agent for cancer prevention and treatment. Food Science & Nutrition, 13(3), e70091.

Hameed, A., Ashraf, F., Anwar, M. J., Amjad, A., Hussain, M., Imran, M., … & Jbawi, E. A. (2024). α-Amylase enzyme inhibition relevant to type II diabetes by using functional yogurt with Cinnamomum verum and Stevia rebaudiana. Food and Agricultural Immunology, 35(1), 2389091.

Khalid, M. U., Sultan, M. T., Khan, W. A., Israr, M., Zafar, N., Noman, A. M., Imtiaz, S., Younis, M., Anwar, M. J., Nayyar, A., Orabi, A. A., & Khalil, N. A. (2024). Nutritional and physico-chemical profiling of Tribulus terristris and its nutraceuticals application. Journal of Population Therapeutics & Clinical Pharmacology, 31(9), 1230–1241.

Faisal, Z., Irfan, R., Akram, N., Manzoor, H. M. I., Aabdi, M. A., Anwar, M. J., … & Desta, D. T. (2024). The multifaceted potential of fenugreek seeds: From health benefits to food and nanotechnology applications. Food Science & Nutrition, 12(4), 2294–2310.

Javed, M. S., Alvi, S. Q., Amjad, A., Sardar, H., Anwar, M. J., Javid, A., … & AbdElgawad, H. (2024). Protein extracted from Moringa oleifera Lam. leaves: Bio-evaluation and characterization as suitable plant-based meat-protein alternative. Regulatory Toxicology and Pharmacology, 146, 105536.

Anwar, M. J., Altaf, A., Imran, M., Amir, M., Alsagaby, S. A., Al Abdulmonem, W., Mujtaba, A., El-Ghorab, A. H., Ghoneim, M. M., Hussain, M., Al Jbawi, E., Shaker, M. E., & Abdelgawad, M. A. (2023). Anti-cancer perspectives of resveratrol: A comprehensive review. Food and Agricultural Immunology, 34(1).

Hameed, A., Anwar, M. J., Khan, M. I., Tarar, O. M., Ali, S. W., Faraz, A., … & Kashif, A. S. (2023). Assessing the impact of camel breed and their grazing habits on the nutritional profile of milk. Pakistan Journal of Agricultural Sciences, 60(2).

Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1… – Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia… – Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML… – J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection… – Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability… – BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processing – Cells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistance – Dev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partners – Mol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expression – Life Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1 – Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Esmail El-Fakharany | cell biology | Best Researcher Award

Published on by Cell Biologist

Prof. Esmail El-Fakharany | cell biology | Best Researcher Award

Prof. Esmail El-Fakharany  , city of scientific research and technological applications , Egypt

Dr. Tamer Abdelrazik is a distinguished researcher in the field of biological sciences and biotechnology, specializing in microbiology, virology, and the preparation of therapeutic agents. He has contributed significantly to the scientific community with over 102 published papers and 16 book chapters. Dr. Abdelrazik holds an esteemed academic position as a part-time research fellow at Pharos University in Alexandria and the Pharmaceutical and Fermentation Industries Development Centre (PFIDC), Alexandria, Egypt. He is also recognized for his leadership as the principal investigator of several funded research projects, focusing on COVID-19 treatments, cancer therapeutics, and environmental technologies. Dr. Abdelrazik’s academic and research achievements have led to his recognition in Stanford’s ranking of the top 2% of impacting scientists globally.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Tamer Abdelrazik demonstrates exceptional research achievements in the fields of biological sciences, biotechnology, and applied biomedical sciences. His impressive track record includes over 102 journal papers and 16 book chapters, with significant contributions to the understanding of antimicrobial agents, cancer therapies, and novel drug delivery systems. Notably, his leadership on projects like “Lactoferrin-Zinc nanocombinations for COVID-19” reflects his innovative approach in addressing global health challenges. Additionally, his inclusion in Stanford’s top 2% ranking of impacting scientists for 2023 showcases his prominence and impact in scientific research. His high H-index (28) and academic supervision of 9 M.Sc. and 13 Ph.D. students highlight his dedication to advancing research and mentoring future scientists.

Areas for Improvement:

While Dr. Abdelrazik’s research output is impressive, expanding the scope of his studies into other emerging fields such as AI-driven drug discovery or sustainability in biomedical engineering could strengthen his scientific legacy. Further interdisciplinary collaborations could also enhance his research portfolio, bringing new perspectives into his work.

Education:

Dr. Tamer Abdelrazik holds an extensive academic background in biological sciences and biotechnology. His early academic training was conducted at recognized institutions in Egypt, followed by advanced studies leading to multiple degrees in the field of microbiology, immunology, and biochemistry. His educational journey enabled him to hone expertise in molecular biology, protein chemistry, tissue culture, and the study of antiviral and anticancer agents. Throughout his academic tenure, Dr. Abdelrazik demonstrated excellence in both theoretical knowledge and experimental practices, often publishing the outcomes of his studies in high-impact journals. He continues to guide future researchers through his supervision of several MSc and Ph.D. students. His education in both the practical and theoretical aspects of biomedical sciences underpins his success as a prominent researcher in various subfields, including therapeutic protein development and environmental biotechnology.

Experience:

Dr. Tamer Abdelrazik’s professional career spans over 15 years, during which he has built a reputation as a leading researcher in the fields of microbiology, biotechnology, and molecular biology. He started his career as a lab specialist at the National Research Centre, Cairo, where he worked from 2006 to 2011. Since 2023, he has held part-time research fellowships at Pharos University and PFIDC, Alexandria, Egypt. In addition to his research duties, he has served as a mentor, advising 9 MSc and 13 Ph.D. students. Dr. Abdelrazik has been the principal investigator on numerous grant-funded projects, focusing on advanced therapies for cancer, COVID-19, and environmental issues. His innovative work, particularly in the development of antimicrobial filters, nanomedicines, and drug delivery systems, has positioned him as a key figure in both academic and industrial research. His career is marked by constant collaboration with national and international research institutions.

Awards and Honors:

Dr. Tamer Abdelrazik has been recognized for his outstanding contributions to scientific research, especially in the fields of biotechnology and medical sciences. He was awarded the prestigious State Encouragement Award in 2019 by the Egyptian Academy of Science and Technology for his advancements in medical technologies. In 2014, he received a certificate from SRTA-City for his significant research achievements and distinguished publications. More recently, Dr. Abdelrazik was ranked in the top 2% of the most impactful scientists globally by Stanford in 2023. These accolades are a testament to his contributions in developing therapeutic agents, including antiviral and anticancer treatments, and his work in environmental health technologies. Dr. Abdelrazik’s recognition by such esteemed institutions highlights his dedication to advancing scientific knowledge and improving human health. These awards solidify his status as a key figure in his field and underscore his influence on global research.

Research Focus:

Dr. Tamer Abdelrazik’s research primarily focuses on advancing medical biotechnology and environmental technologies. He is particularly known for his work in virology, microbiology, and the development of antiviral agents, with a focus on COVID-19. Additionally, his research addresses cancer therapeutics, especially the formulation of nano-complexes to treat various carcinomas. Dr. Abdelrazik’s work includes the investigation and development of novel bioactive compounds such as antimicrobial agents and the fabrication of therapeutic proteins and enzymes. His ongoing projects also explore environmental applications, such as antimicrobial air filters integrated with air-conditioning systems and water purification membranes. His research aims to merge scientific knowledge with practical solutions to address global health challenges. Moreover, he is dedicated to enhancing the delivery of therapeutic agents through innovative drug delivery systems, with a special emphasis on tissue culture, protein chemistry, and immunology.

Publications Top Notes:

  1. Interaction of Jania rubens Polyphenolic Extract as an Antidiabetic Agent with α-Amylase, Lipase, and Trypsin 🧑‍🔬🍀 (2024)
  2. Influence of Cedar Essential Oil on Polyvinyl Alcohol/Cedar Oil/Kaolin Composite Hydrogels 🌲💧 (2023)
  3. Preparation and Physicochemical Characterization of Gelatin–Aldehyde Derivatives 🧪🧬 (2022)
  4. Fatty N-Hexadecanyl Chitosan Derivatives for Biomedical Applications 🧬💉 (2022)
  5. Development of Polyvinyl Alcohol/Kaolin Sponges for Wound Healing Promotion 💉🌱 (2021)
  6. Green Cation Exchange Membrane Doped with Ceramic Nanotubes for Fuel Cells 🔋🔬 (2021)
  7. Effects of Octenyl Succinic Anhydride on Rice Starch Emulsions 🍚💡 (2020)
  8. Antimicrobial Activity of Modified Aminated Chitosan with Aromatic Esters 🦠🍃 (2019)
  9. Cinnamyl O-amine Functionalized Chitosan for Drug Delivery 💊🌿 (2019)
  10. Development of Polyelectrolyte Membranes for Direct Methanol Fuel Cells 🔋🧪 (2019)
  11. Smart Alginate/Chitosan Microcapsules for Colon-Specific Drug Delivery 💊👨‍🔬 (2019)

Conclusion:

Dr. Abdelrazik’s outstanding academic and research contributions make him a highly deserving candidate for the Research for Best Researcher Award. His consistent achievements in high-impact publications, leadership in research projects, and innovative scientific discoveries have placed him at the forefront of his field, solidifying his reputation as an influential researcher.

 

 

 

Arvind Singh Negi | Medicinal chemistry | Outstanding Scientist Award

Published on by Cell Biologist

Dr. Arvind Singh Negi | Medicinal chemistry | Outstanding Scientist Award

Dr. Arvind Singh Negi  , csir-cimap , India

Dr. Arvind Singh Negi, born on January 1, 1970, is a prominent scientist in the field of medicinal chemistry, currently serving as Chief Scientist and Head of the Phytochemistry Division at CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India. With a distinguished academic background and over three decades of experience, he specializes in natural product chemistry and the development of cancer chemotherapeutics. Dr. Negi has published extensively, contributing significantly to the understanding of plant-based medicinal compounds. His work has garnered numerous accolades, reflecting his commitment to advancing science in medicinal chemistry and natural products.

Publication Profile

Google Scholar

Strengths for the Award

Dr. Arvind Singh Negi possesses a robust academic background and extensive experience in medicinal chemistry, particularly in the development of cancer therapeutics from natural products. His impressive publication record, with over 106 research papers and significant citations, showcases his impact on the field. His leadership as Chief Scientist at CSIR-CIMAP reflects his ability to drive innovative research initiatives. Additionally, his multiple prestigious awards and fellowships, including recognition from the Royal Society of Chemistry and the National Academy of Sciences, underscore his scientific contributions and collaborations on a global scale.

Areas for Improvement

While Dr. Negi’s research achievements are commendable, expanding his outreach to interdisciplinary collaborations could enhance the applicability of his findings. Increasing engagement in public awareness and education on the significance of his research in medicinal chemistry could also strengthen his influence beyond academic circles. Further diversification of research themes might attract funding and foster novel explorations in related areas.

Education 

Dr. Negi completed his B.Sc. in Physics, Chemistry, and Mathematics from Lucknow Christian Degree College, University of Lucknow, in 1989. He excelled academically, earning his M.Sc. in Chemistry with First Rank from the same university in 1991. He further pursued a Ph.D. in Medicinal Chemistry at CSIR-Central Drug Research Institute, obtaining his degree in 1999. His educational journey includes significant research experiences, starting as a Scientist at ICAR-Indian Grassland and Fodder Research Institute in 1995. Dr. Negi has continuously advanced his knowledge and expertise through various fellowships, including prestigious opportunities at renowned international institutions, shaping his specialization in organic and natural product chemistry.

Experience 

Dr. Arvind Singh Negi boasts over 25 years of research experience in the field of medicinal chemistry. He began his career as a Scientist at ICAR-Indian Grassland and Fodder Research Institute in 1995, moving on to join CSIR-CIMAP in 2000. Over the years, he has progressed through various ranks, becoming a Chief Scientist in 2018. His extensive experience encompasses research and development of natural product-based pharmaceuticals, focusing on cancer therapeutics and organic synthesis. Dr. Negi has also supervised multiple Ph.D. theses and collaborated with national and international researchers, contributing to over 100 research publications. His leadership in the Phytochemistry Division has fostered innovative research projects, enhancing the institute’s reputation in medicinal plant research.

Awards and Honors 

Dr. Negi’s exemplary contributions to science have been recognized through numerous awards and honors. He was awarded the CSIR-JRF and Lectureship in 1991, followed by the ICAR Assistant Professorship in 1994. His research has earned him the Bioorganic & Medicinal Chemistry Most Cited Paper Award three times (2007, 2008, 2010) from Elsevier Press. He has received prestigious fellowships, including the ICS-UNIDO Fellowship in Italy (2008) and the Raman Research Fellowship in the USA (2010). Dr. Negi became a member of the National Academy of Sciences (NASI) in 2013 and was later invited to the Royal Society of Chemistry, achieving Fellow status in 2022. His recognition underscores his significant impact on medicinal chemistry and natural product research.

Research Focus 

Dr. Arvind Singh Negi specializes in medicinal chemistry, with a primary focus on the development of cancer chemotherapeutics. His current research involves designing target-specific molecules to modulate microtubule dynamics, a crucial aspect of cancer treatment. By harnessing the therapeutic potential of natural products, he investigates plant-based compounds that exhibit anticancer properties. His work encompasses extensive studies on the chemical and biological profiles of medicinal plants, contributing to the discovery of novel anticancer agents. Dr. Negi’s innovative approaches aim to bridge the gap between traditional knowledge and modern scientific methodologies, making significant strides in the field of phytochemistry. His research not only enhances our understanding of cancer therapeutics but also promotes the exploration of sustainable and effective treatments derived from nature.

Publication Top Notes

  1. Plant-based anticancer molecules: A chemical and biological profile of some important leads 🌱
  2. Antimicrobial potential of Glycyrrhiza glabra roots 🌿
  3. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads 🌿
  4. Current status on development of steroids as anticancer agents 💊
  5. Antifungal activity of Glycyrrhiza glabra extracts and its active constituent glabridin 🌿
  6. Gallic acid-based indanone derivatives as anticancer agents 🌿
  7. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis 🌿
  8. Natural antitubulin agents: Importance of 3, 4, 5-trimethoxyphenyl fragment 🌱
  9. Synthesis of chalcone derivatives on steroidal framework and their anticancer activities 💊
  10. Synthesis of 1-(3′,4′,5′-trimethoxy) phenyl naphtho[2,1b]furan as a novel anticancer agent 🌱
  11. Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine 🌱
  12. An insight into medicinal chemistry of anticancer quinoxalines 💊
  13. Antitubercular potential of some semisynthetic analogues of phytol 🌱
  14. Defective in cuticular ridges (DCR) of Arabidopsis thaliana, a gene associated with surface cutin formation, encodes a soluble diacylglycerol acyltransferase 🌱
  15. Nutritive evaluation of some nitrogen and non-nitrogen fixing multipurpose tree species 🌳
  16. Antiproliferative and antioxidant activities of Juglans regia fruit extracts 🌰
  17. Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition 💊
  18. A bioactive labdane diterpenoid from Curcuma amada and its semisynthetic analogues as antitubercular agents 🌿
  19. Anticancer activity and toxicity profiles of 2-benzylidene indanone lead molecule 💊
  20. A promising anticancer and antimalarial component from the leaves of Bidens pilosa 🌿

Conclusion

Dr. Arvind Singh Negi is an exemplary candidate for the Outstanding Scientist Award. His pioneering work in medicinal chemistry, along with his dedication to advancing cancer therapeutics through innovative research, positions him as a leader in the field. With strategic enhancements in collaboration and outreach, his impact could extend even further, benefiting both scientific communities and public health.

 

 

Yuan Ma | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Prof Yuan Ma | Cell Death Pathway | Best Researcher Award

Prof Yuan Ma , Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University , China

Yuan Ma is a prominent Professor in the Department of Respiratory and Critical Care Medicine at The First Affiliated Hospital of Nanjing Medical University, China. With a medical background and a focus on bronchial asthma, Dr. Ma has made significant contributions to understanding the mechanisms of airway inflammation and remodeling. Through extensive research, he aims to identify novel molecular targets for asthma therapies. His work has been recognized internationally, underscoring his dedication to advancing clinical applications in respiratory medicine.

Publication Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Yuan Ma has a robust academic background as a Professor in Respiratory and Critical Care Medicine. His focus on airway inflammation and remodeling in asthma is critical, given the increasing prevalence of respiratory diseases.
  2. Publication Record: With 25 articles in domestic journals and 13 in international journals, his publication record demonstrates both local and global recognition of his work. Notable articles in high-impact journals underscore the significance and relevance of his research.
  3. Innovative Contributions: Ma’s identification of necroptosis-related targets in asthma and the discovery of potential therapeutic compounds indicate significant advancements in the understanding and treatment of asthma, contributing to both academic knowledge and clinical practice.
  4. Grant Funding: Successfully presiding over projects funded by the National Natural Science Foundation of China highlights his ability to secure funding for impactful research, a crucial aspect of a successful research career.
  5. Patents: The issuance of 13 patents illustrates his innovative capacity and the potential for practical applications of his research findings.

Areas for Improvement

  1. Broader Collaborations: While Ma has made significant contributions, fostering collaborations with researchers from diverse fields could enhance interdisciplinary insights and expand the impact of his work.
  2. Professional Memberships: Engaging in professional organizations could provide networking opportunities and enhance visibility in the research community, further strengthening his position.
  3. Public Outreach: Increasing public engagement and dissemination of research findings could elevate awareness about asthma and his innovations, potentially leading to broader societal impact.

Education 

Dr. Yuan Ma obtained his medical degree from a prestigious institution, followed by specialized training in respiratory medicine. He completed his PhD with a focus on airway diseases, where he gained insights into the cellular and molecular mechanisms underlying asthma. Throughout his academic journey, Dr. Ma has cultivated a robust foundation in both clinical practice and research methodology, allowing him to bridge the gap between laboratory findings and patient care. His continuous pursuit of knowledge in respiratory health has led him to engage in various professional development opportunities, enhancing his expertise and contributing to his role as a leader in his field.

Experience 

Dr. Yuan Ma has extensive experience in both clinical and research settings, spanning over a decade. He has presided over significant research projects funded by the National Natural Science Foundation of China, exploring the pathogenesis of asthma and potential therapeutic interventions. His impressive track record includes 25 publications in national journals and 13 in international peer-reviewed journals, showcasing his commitment to advancing respiratory medicine. As a professor, he mentors medical students and residents, fostering the next generation of researchers and clinicians. His collaborative work with national and international peers has enriched his research, contributing to innovative approaches in asthma treatment. Additionally, his contributions to patent development demonstrate his drive to translate research findings into practical applications for better patient outcomes.

Research Focus 

Dr. Yuan Ma’s research primarily focuses on the mechanisms of airway inflammation and remodeling in bronchial asthma. He investigates necroptosis-related biomarkers and their regulatory mechanisms, aiming to identify novel therapeutic targets. His work encompasses exploring molecular compounds that can effectively modulate these targets, enhancing asthma diagnosis and treatment options. Dr. Ma’s innovative studies delve into the role of oxidative stress and MAPK signaling pathways in airway smooth muscle cell behavior. By examining the intricate interactions within the airway microenvironment, he seeks to uncover underlying processes that contribute to asthma exacerbations. His research has significant implications for developing targeted therapies, addressing the unmet needs of asthma patients, and ultimately improving clinical outcomes in respiratory medicine.

Publications Top Notes

  1. Screening, identification and targeted intervention of necroptotic biomarkers of asthma. 📄
  2. Caffeic acid phenethyl ester alleviates asthma by regulating the airway microenvironment via the ROS-responsive MAPK/Akt pathway. 🌱
  3. Morin Attenuates Ovalbumin-induced Airway Inflammation by Modulating Oxidative Stress-responsive MAPK Signaling. 🩺
  4. A case of male primary pulmonary choriocarcinoma. 🦠
  5. Implication of dendritic cells in lung diseases: immunological role of Toll-like receptor 4. 🔬
  6. Glomus tumors of the trachea: 2 case reports and a review of the literature. 📚
  7. Diosmetin prevents TGF-β1-induced epithelial-mesenchymal transition via ROS/MAPK signaling pathways. 🧬
  8. SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients. 🦠
  9. Characteristics of H7N9 avian influenza pneumonia: a retrospective analysis of 17 cases. 📊
  10. Galangin attenuates airway remodeling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. 🌿
  11. Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma. 🌙
  12. Single-agent Maintenance Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-analysis. 🧑‍⚕️
  13. Effect of diosmetin on airway remodeling in a murine model of chronic asthma. 🐭

Conclusion

Yuan Ma’s exceptional research contributions in understanding and treating asthma position him as a strong candidate for the Best Researcher Award. His extensive publication record, innovative findings, and successful grant applications reflect a commitment to advancing respiratory medicine. Addressing areas for improvement could further enhance his profile and influence in the field. Overall, Ma’s achievements warrant recognition, and he is well-suited for this prestigious award.